Bortezomib inhibits bone marrow-derived dendritic cells

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
• Dendritic cells (DCs) play a crucial role in initiating and perpetuating GVHD.
• Targeting DC function presents a therapeutic strategy for GVHD prevention.

Purpose of the Study:

• To investigate the effects of the proteasome inhibitor Bortezomib on dendritic cell (DC) function in vitro.
• To evaluate Bortezomib's potential as a therapeutic agent for graft-versus-host disease (GVHD).

Main Methods:

• Primary mouse DCs were cultured and treated with Bortezomib.
• DC proliferation, co-stimulatory molecule expression (CD80, CD86), and cytokine secretion (IL-12, TNF-α) were assessed.
• DC-mediated T cell activation was evaluated using mixed lymphocyte reaction assays.
• Nuclear factor-kappa B (NF-κB) translocation was analyzed by electrophoretic mobility shift assay (EMSA).

Main Results:

• Bortezomib inhibited DC proliferation in a dose- and time-dependent manner.
• Bortezomib suppressed LPS-induced expression of CD80, CD86, and secretion of IL-12 and TNF-α by DCs.
• Bortezomib reduced the capacity of DCs to activate T cells.
• Bortezomib inhibited the nuclear translocation of NF-κB in DCs.

Conclusions:

• Bortezomib effectively impairs multiple functions of dendritic cells.
• Bortezomib demonstrates potential as a therapeutic strategy to control GVHD following allo-HSCT.